Companies / Industrials
NOC
Northrop Grumman
Aerospace & Defense
Aerospace & DefenseAnalysis in progress
In progress
We are decoding this company's strategy and relationships
New analyses are published every weekday. Founding members get them first.
Business at a glance
Operating-health scores describe reported fundamentals on a 0–100 scale. They are not a rating of the stock. How they work
Operating health55
Growth36
Profitability43
Cash generation48
Balance sheet51
Dilution control95
Key ratios and five-year financials
Latest quarter revenue YoY (2026-09-30)6.7%Revenue growth (FY)2.2%Revenue CAGR (3y)4.7%Gross margin—Operating margin10.8%Net margin10.0%Free cash flow margin7.9%R&D / revenue2.6%Stock comp / revenue0.3%Net debt / operating cash flow2.49xCurrent ratio1.10Diluted share count change-2.4%
| Fiscal year ending | FY 2021-12 | FY 2022-12 | FY 2023-12 | FY 2024-12 | FY 2025-12 |
|---|---|---|---|---|---|
| Revenue | $35.7B | $36.6B | $39.3B | $41.0B | $42.0B |
| Operating income | $5.7B | $3.6B | $2.5B | $4.4B | $4.5B |
| Net income | $7.0B | $4.9B | $2.1B | $4.2B | $4.2B |
| Operating cash flow | $3.6B | $2.9B | $3.9B | $4.4B | $4.8B |
| Capital expenditure | $1.4B | $1.4B | $1.8B | $1.8B | $1.4B |
| Free cash flow | $2.2B | $1.5B | $2.1B | $2.6B | $3.3B |
| R&D | $1.1B | $1.2B | $1.2B | $1.1B | $1.1B |
| Stock-based comp | $94M | $99M | $87M | $101M | $119M |
| Buybacks | $3.7B | $1.5B | $1.5B | $2.5B | $1.6B |
| Dividends | $983M | $1.1B | $1.1B | $1.2B | $1.3B |
| Cash | $3.5B | $2.6B | $3.1B | $4.4B | $4.4B |
| Total debt | $12.8B | $13.9B | $13.9B | $17.9B | $16.2B |
| Equity | $12.9B | $15.3B | $14.8B | $15.3B | $16.7B |
StratGraph publishes general, impersonal research about public companies based on public filings. It is not investment advice, not a recommendation to buy, sell or hold any security, and not tailored to any reader's circumstances. Content may contain errors and may be partly generated with AI tools; verify against the original filings, which are linked. Authors may not trade securities discussed within the window set by our trading policy. Full disclaimer.